Qiana Paris

No DFS Benefit With Adjuvant Durvalumab in Early NSCLC

September 14, 2024

Adjuvant durvalumab (Imfinzi) provided no significant improvement in disease-free survival compared with placebo following resection in patients with early-stage non-small...

Qiana Paris

No DFS Benefit With Adjuvant Durvalumab in Early NSCLC

Oncologica to advance urine-based prostate cancer screening test

Not just a normal part of aging: Dizziness in older adults is linked to higher risk of future falls

FDA Approves Benralizumab for EGPA Vasculitis Indication

Study finds early puberty linked to higher risk for HS

CGM Cuts Hospitalization in T2D, Even in Non-Insulin Treated

Budget FY25: Pharmaceuticals sector needs a major boost with increased focus on R&D and innovation

Dental veneers: Everything you need to know

Cheeky diet soft drink getting you through the work day? Here’s what that may mean for your health

UK teenagers get two-thirds of their calories from ultra-processed foods—new study

Some have called this area a birthing ‘desert.’ A nurse midwife is working to change that

Oncologica to advance urine-based prostate cancer screening test

Not just a normal part of aging: Dizziness in older adults is linked to higher risk of future falls

FDA Approves Benralizumab for EGPA Vasculitis Indication

Study finds early puberty linked to higher risk for HS

CGM Cuts Hospitalization in T2D, Even in Non-Insulin Treated

About PhaMed

Recent News

You may have missed

About PhaMed

Recent News

Categories